LMR Partners’s Theriva Biologics TOVX Stock Holding History

LMR Partners’s Portfolio TOVX Stock Details TOVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-39	Closed	-$194K	–	541
2017 Q2	$194K	Buy	+39	New	+$194K	0.01%	529
2014 Q2	–	Sell	-11	Closed	-$257K	–	560
2014 Q1	$257K	Buy	+11	New	+$228K	0.04%	207

Other funds holding TOVX

Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

EDRH

Edmond de Rothschild Holding Chambesy, Switzerland $6.91B AUM 19.7% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

ECM

Element Capital Management New York $1.05B AUM 5.05% 1-Year Est. Return

LMR Partners's TOVX Position: Q3 2017 in Review

LMR Partners sold out of Theriva Biologics (TOVX) in Q3 2017, closing a stake of 39 shares — an estimated $194K sold.

LMR Partners first reported a position in TOVX in Q1 2014 and held it in 2 quarters. The position peaked at $257K in Q1 2014. 51 funds tracked by Wall St. Rank hold TOVX as of Q3 2017.

LMR Partners reported no remaining Theriva Biologics position as of Q3 2017 after selling out during the quarter.
LMR Partners sold 39 Theriva Biologics shares in Q3 2017, an estimated $194K.
LMR Partners first reported a position in Theriva Biologics in Q1 2014 and held it in 2 quarters.
LMR Partners's Theriva Biologics position peaked at $257K in Q1 2014.
51 funds tracked by Wall St. Rank held Theriva Biologics as of Q3 2017.

Based on LMR Partners's 13F filing for Q3 2017, filed 9 Nov 2017.